Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Just another little observation….
ABDX latest blog was about security of supply chain, written by our COO Mark Jones - https://www.abingdonhealth.com/ensuring-your-critical-components-are-protected-the-importance-of-supply-agreements/
Whist this is undated, it appears to me to be a new news release from a company called Rosti, who have partnered with is for injection moulding.
https://rosti.com/rosti-uk-secures-exciting-new-project-with-abingdon-health/
Just interesting that focus lately has been on supply and security of manufacturing components.
I see Wynbore is still trying to get a foothold..
Set your phasers to stun lol
Goodness, springing upwards week by week. Won't be long now!
In that case we need to get 80p...... so £8m-12m profit to support that price, I guess.
12 months ... (maybe....) :0))
(Just my opinion DYOR etc)
Wyndrum, IIs won't even glance at a stock unless it has a mcap of > £100 mill as there just isn't enough liquidity for their size of dealing.
Closed at 11p today...still on track to have a go at 12p. (Hopefully tomorrow. It would be bullish if it did.)
Hi Muck, yes it all looks to be coming together, and although at the moment, I can't see what the valuation could be, it would seem to be at a substantial premium to where it is now.
I think this is such a small cap that due to its size it HAS to go under the radar of ii's but with a couple more promising RNS's confirming extra sales order/contracts in effect making no more cash raises likely, will cause a re-rate and then as the mkt cap increases so it will then creep on to more analysts spread sheets.
So I wait for the virtuous circle that I believe has actually started (as foretold by the charts! ha ha :0))
atb
Hi Wyn
Agree - getting regulatory approval is like wading through treacle and all sorts of extra requests can delay things. But the point still remains valid - it’s reasonable to think we’re entering a time window when a decision might be made.
And the Times of Israel quoted Krieff last month as saying Salistick is currently being “positioned” in the States.
How approval might directly affect ABDX I don’t know - we’re unlikely to be a US distributor (although that would be amazing!), but we will still be manufacturing.
Hi Muck,
fwiw, but AGL went through the FDA thing. I think (I empasize think), that the FDA have a 150 days also to ask more questions or get more info if they feel they need it, rather than just a 150 day dead line for a decision. If they do request more data or whatever I believe the clock is rest. Again from memory, AGL waited over a year over the 150d days before they eventually succeeded with FDA approval And to be fair it was during covid so there exceptional time delays on the part of the FDA as well, so who knows.....
Just another small observation…
We know that Salignostics got UKCA approval in March 23, and that they also have CE. We also know they had initial meetings with the FDA by at least November 21.
Now, I’m not entirely sure what FDA approval pathway they’d have to follow, and so what additional requirements the FDA might have over and above conformity assessments in the U.K/EU
What I do know is that for a De Novo application, being the pathway for a device with no existing substantial equivalent, the FDA aim to give a decision within 150 days of having all necessary information.
So if we got UKCA in March 23, I think it’s reasonable to think an FDA decision can’t be too far away (assuming there’s been no hiccups!)
Nice steady climb over the past month though, so let's hope the trend continues into the next piece of good news which looks fairly imminent judging from all the fabulous research Muck has been doing.
Just a slight more volume been sold today, tomorrow hopefully trend will reverse.
You're great Muck165! You sure are helpful. Hope youre getting out in the fresh air too as this share will come good when it's ready IMO! Exciting stuff - and just so happy that if newcomers do actually check out the opinions of shareholders on this board, they will find the majority of posts are so positive and forward looking and, as a bonus, so civilised lol .
1. Boots have little pop up that tells you how many times an item has been viewed, and how many times its been added to basket in the last 24 hours. I've been watching this daily (sad I know) since our Vit D and Iron tests launched, and we are consistently ahead of the MHC equivalents, despite no price differential. Boots are selling between 25 and 50 of each product each day, online only.
Loop - - their CEO has been heavily publicising a speaking session he is delivering at the EIT Health Summit on 18-19 April. Perhaps we might get a UKCA announcement before then?
As I say, just little observations...
More good news from the Upfront CEO today
https://www.linkedin.com/posts/gonzaloladreda_timeislife-activity-7183373180240019457-NJE-?utm_source=share&utm_medium=member_desktop
Don’t know what happened there! Just look at the recommendation letter on page 20, which has come from one of the largest medical device manufacturers in the world.
I lied! Last one, promise!
On page 20 of the presentation Upfront show a letter of recommendation from Medtronic, which says “The current stroke penetration rate of of
Final one from me, but I came across this pitch update because a company called Odelle posted this on LinkedIn (which Yates liked)
https://www.linkedin.com/posts/odelle-technology_excellence-diagnostics-activity-7183021230294192129-2eH9?utm_source=share&utm_medium=member_desktop
So it’s interesting to see what Odelle do, and the companies they’ve worked with
https://odelletechnology.com/about-us/
Overall it’s really obvious that Upfront have a very well planned and professional roadmap to market, involving professional and experienced consultants and with support of regulatory health powers that be. Great customer for us.
Also worth noting again that one of the benefits of IDAP is the potential for “Exceptional Use Authorisation” from the MRHA, which could come sooner than anyone expects.
https://www.gov.uk/government/publications/the-innovative-devices-access-pathway-idap/the-innovative-devices-access-pathway-idap-pilot-phase
Hi Apre
Everything you note is certainly relatable, but it’s the numbers in this latest update to their pitch that excite me, forecasts though they are.
And yes, whilst the trials are important and will take a little more time, it doesn’t appear to delay UKCA or CE applications which, according to this and prior versions of the pitch (see earlier in the thread) will be done this quarter. And then of course there’s IDAP, so at least in respect of UKCA I think we can expect a fast track approach to approval, fully supported by all the heavyweight national health bodies.
But like you, I’m no accountant and would love it if someone could shed more insight on the forecasts as they might relate to us.
Hi Muck, more terrific research there, thank you.
I am no accountant, so looking through the monster figures they are showing leaves me a little dazed (page 22). I have to focus on other layman's points like the improved diagnosis times and improved outcomes (pages 10 to 14), the comparison to competitors (page 18), the reference to the US 'go-to' market, especially the intended application for breakthrough device designation this year (page 20) which I find easier to relate to. All very impressive.
Again, as a non-accountant, I see the potential returns being suggested and think that a paltry £3m investment seems like small potatoes. Am I reading this wrong? There must be plenty of HNW individuals or venture capitalists, let alone institutions who could rustle up that kind of money . . . given the potential . . . no?
I did note from the road map (page 24) that UK clinical trials will not be complete until late 2024ish and US clinical trial in 2025, so a little more time required to dot the t's and cross the i's. But they are pitching for UK commercialisation around end 2024/start 2025 . . . which would be huge. Got to be a few tasty RNS's between now and then, surely. Presumably including a successful fund raise.
So, it would appear that Upfront have again updated their pitch deck.
I would encourage anyone here to read it, because this is the first time they have put forward financial projections - see page 22 of the report. I'd really appreciate comment anyone might have.
Apart from the size of the numbers, the one thing that stood out for me is that they are quoting "net revenue" figures, which they say are quoted after 30-40% distributor fees. No guarantees of course, but I would imagine we would be one of those distributors, as well as a manufacturer. Give the size of the numbers, those fees could be very significant indeed and, as Yates has said, recur year on year.
Upfront are very clearly on a funding drive at the moment to raise £3m., having been pitching all over the place. It will be interesting to see if they get it away, although I have little doubt they will.
https://media.licdn.com/dms/document/media/D4E1FAQGlCe3DkrR-fA/feedshare-document-pdf-analyzed/0/1712565286749?e=1713398400&v=beta&t=aihEAC-lBZsZNPQoOSlPvZgOm_-z5Pc44_JfLj2ALKs
Just one of the horses we will soon have running, and certainly one of my favourites.
yes they were set up has the head of the uk diagnostics consortium (government ******s) i went through all that with odx and abingdon. but looks like things are coming good finally and at a snip from when they floated over£1 gla ill certainly be holding for quite a while
Keeping it real of course but recognising quality when it's staring you in the face. This company has shown its metal through adversity .It had a much higher value before covid struck because it was always worth it. Those who know its story and want to wait a while, know they are onto a very, very good thing.
With you there Muck165. I'm sorry for tho